Ippei Miyagawa1, Shingo Nakayamada1, Yoshiya Tanaka2. 1. The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, 807-8555, Japan. 2. The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, 807-8555, Japan. tanaka@med.uoeh-u.ac.jp.
Abstract
PURPOSE OF REVIEW: This review describes previously reported findings on optimal biologic agent selection for psoriatic arthritis (PsA) treatment and outlines our approach to developing precision medicine techniques for targeted treatment of this disease. RECENT FINDINGS: Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA. Although several studies have suggested specific predictors of treatment responses to each biologic, how biologics are differentially chosen in each patient remains unclear. Recent reports indicate the possibility of treating PsA using precision medicine based on individual immunological phenotypes. Because PsA exhibits numerous symptoms, selecting an optimal biologic for each patient may be important. The establishment of appropriate selection guidelines will require further clinical trials.
PURPOSE OF REVIEW: This review describes previously reported findings on optimal biologic agent selection for psoriatic arthritis (PsA) treatment and outlines our approach to developing precision medicine techniques for targeted treatment of this disease. RECENT FINDINGS: Clinical trials have reported the effectiveness of numerous biologics with different targets, such as tumor necrosis factor-α, interleukin (IL)-17A, IL-17 receptor, IL-12/23(p40), and IL-23(p19) for the treatment of PsA. Although several studies have suggested specific predictors of treatment responses to each biologic, how biologics are differentially chosen in each patient remains unclear. Recent reports indicate the possibility of treating PsA using precision medicine based on individual immunological phenotypes. Because PsA exhibits numerous symptoms, selecting an optimal biologic for each patient may be important. The establishment of appropriate selection guidelines will require further clinical trials.
Entities:
Keywords:
Biologics; Precision medicine; Psoriatic arthritis; T cells; Treatment